What is the treatment and prognosis for a 2mm Grade 1 invasive carcinoma of the breast with a Nottingham histologic score of 1 for glandular/tubular differentiation, score 2 for nuclear pleomorphism, and score 1 for mitotic rate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment and Prognosis for 2mm Grade 1 Invasive Breast Carcinoma

Breast-conserving therapy with sentinel lymph node biopsy is the recommended treatment for this 2mm Grade 1 invasive ductal carcinoma, which has an excellent prognosis with >95% 5-year survival rate. 1

Pathological Assessment

  • The biopsy shows a Grade 1 invasive carcinoma of no specific type (ductal) with a Nottingham histologic score of 4 (1+2+1), which is associated with excellent prognosis 2
  • The tumor is very small (2mm), which is classified as T1a (tumor >1mm but ≤5mm) 3
  • The low mitotic count (score 1) is particularly significant as mitotic activity is one of the strongest prognostic indicators for early breast cancer outcomes 4
  • Grade 1 tumors have significantly better survival rates compared to higher grade tumors, even within the same histologic type 5

Surgical Management

  • Breast-conserving surgery (lumpectomy) with sentinel lymph node biopsy is the standard approach for this small, early-stage tumor 3, 1
  • Proper orientation of the surgical specimen with markers is essential to ensure negative margins while preserving breast tissue 3
  • Specimen radiography should be performed intraoperatively to confirm complete removal of any mammographic abnormalities 1
  • Sentinel lymph node biopsy is recommended for axillary staging, as this is an invasive carcinoma 3

Adjuvant Therapy Considerations

  • Radiation therapy following breast-conserving surgery is generally recommended to reduce local recurrence risk 3, 1
  • Endocrine therapy should be considered if hormone receptor testing reveals ER/PR positivity 3
  • For this very small (2mm) Grade 1 tumor, adjuvant chemotherapy is typically not indicated unless other high-risk features are present 3
  • Hormone receptor and HER2 status should be determined to guide adjuvant therapy decisions 3

Prognosis

  • Grade 1 invasive carcinomas have an excellent prognosis, with survival rates approaching that of the general population of the same age 6
  • The 2mm tumor size is highly favorable, as tumor size directly correlates with prognosis 3, 1
  • The low mitotic count (score 1) is associated with better tumor-free survival 4
  • The combination of small tumor size and Grade 1 histology places this case in the excellent prognostic group 2, 5

Follow-up Recommendations

  • Regular clinical examinations every 4-6 months for the first 5 years, then annually 1, 7
  • Annual mammography of both breasts 1, 7
  • No indication for intensive surveillance imaging (CT, bone scans, etc.) in this early-stage disease with excellent prognosis 3

Common Pitfalls to Avoid

  • Overtreatment with chemotherapy for very small, low-grade tumors that have excellent prognosis with local therapy alone 3, 1
  • Inadequate surgical margins leading to re-excision; proper specimen orientation and intraoperative assessment are critical 3, 1
  • Failure to perform hormone receptor and HER2 testing, which are essential for determining appropriate adjuvant therapy 3

References

Guideline

Treatment Approach for Invasive Distal Carcinoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Classification and grading of invasive breast carcinoma.

Verhandlungen der Deutschen Gesellschaft fur Pathologie, 2005

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Role of mitotic counts in the grading and prognosis of the breast cancer.

Indian journal of pathology & microbiology, 2002

Research

Special types of invasive breast cancer, with clinical implications.

The American journal of surgical pathology, 2003

Guideline

Tratamento do Carcinoma Ductal Invasivo de Mama

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.